Skip to main content
. 2024 Jan 3;19:11. doi: 10.1186/s13018-023-04492-z

Table 3.

Results of secondary seed statement review

Revised seed statement Agreement (Rated as 7–9, or “highly appropriate”)
Secondary pharmacological management may consist of tramadol, when tolerated and in the absence of contraindication(s) 9/11 (82.0%)
Secondary pharmacological management may consist of duloxetine, when tolerated and in the absence of contraindication(s) 7/11 (64.0%)*

*Indicates consensus was not reached